Life Science Alliance

News

19 May 2020
A recent study conducted by the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) discovered a novel genetic biomarker which can predict the survival of head and neck cancer patients. There are over 0.7 million new head and neck squamous cell carcinoma (HNSCC) cases globally each year. However, currently there is no clinical implementation of any genetic biomarker to predict outcomes for these patients after standard treatment. A study led by Professor Vivian Wai Yan LUI, an expert in genomic medicine and Associate Professor of the School of Biomedical Sciences at CU Medicine, and her research team, has identified that mitogen activated protein kinase (MAPK) pathway mutations found in almost 20% of HNSCC patients can predict favourable clinical outcomes with standard therapy. Their survival also doubled when compared with other patients. The finding has just been published in the journal Life Science Alliance.
Loricrin keratoderma sample
02 Apr 2019
Pathogenic gene mutations causing a type of intractable skin disease can be eliminated from some parts of patients’ skin as they age, according to Hokkaido University researchers and their collaborators in Japan. This represents a form of natural gene therapy.

Events

Sorry, no events coming up for this topic.

Researchers

Sorry, no researchers coming up for this topic.